Publicaciones en colaboración con investigadores/as de Hospital for Sick Children (12)

2024

  1. ATM germ line pathogenic variants affect outcomes in children with ataxia-telangiectasia and hematological malignancies

    Blood, Vol. 144, Núm. 11, pp. 1193-1205

2021

  1. Global characteristics and outcomes of SARS-CoV-2 infection in children and adolescents with cancer (GRCCC): a cohort study

    The Lancet Oncology, Vol. 22, Núm. 10, pp. 1416-1426

2020

  1. Neuroinflammatory Disease as an Isolated Manifestation of Hemophagocytic Lymphohistiocytosis

    Journal of Clinical Immunology, Vol. 40, Núm. 6, pp. 901-916

2019

  1. A multicenter study of patients with multisystem Langerhans cell histiocytosis who develop secondary hemophagocytic lymphohistiocytosis

    Cancer, Vol. 125, Núm. 6, pp. 963-971

2017

  1. Confirmed efficacy of etoposide and dexamethasone in HLH treatment: Long-Term results of the cooperative HLH-2004 study

    Blood, Vol. 130, Núm. 25, pp. 2728-2738

  2. Development and Initial Validation of the Macrophage Activation Syndrome/Primary Hemophagocytic Lymphohistiocytosis Score, a Diagnostic Tool that Differentiates Primary Hemophagocytic Lymphohistiocytosis from Macrophage Activation Syndrome

    Journal of Pediatrics, Vol. 189, pp. 72-78.e3

2016

  1. Expert consensus on dynamics of laboratory tests for diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis

    RMD Open, Vol. 2, Núm. 1

  2. Somatic DICER1 mutations in adult-onset pulmonary blastoma

    European Respiratory Journal

2015

  1. Lack of bone lesions at diagnosis is associated with inferior outcome in multisystem langerhans cell histiocytosis of childhood

    British Journal of Haematology, Vol. 169, Núm. 2, pp. 241-248

  2. Management and Outcome of Patients With Langerhans Cell Histiocytosis and Single-Bone CNS-Risk Lesions: A Multi-Institutional Retrospective Study

    Pediatric Blood and Cancer, Vol. 62, Núm. 12, pp. 2162-2166

2013

  1. Langerhans cell histiocytosis (LCH): Guidelines for diagnosis, clinical work-up, and treatment for patients till the age of 18 years

    Pediatric Blood and Cancer, Vol. 60, Núm. 2, pp. 175-184

  2. Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis

    Blood, Vol. 121, Núm. 25, pp. 5006-5014